Overview

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
Phase:
Phase 2
Details
Lead Sponsor:
Arrowhead Pharmaceuticals